The primary purpose of this study is to assess the safety and tolerability of RP-6306 in combination gemcitabine, in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-6306 in combination with gemcitabine, identify a recommended phase 2 dose (RP2D) and preferred schedule, examine preliminary pharmacokinetics (PK) and assess anti-tumor activity.
Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination With Gemcitabine for the Treatment of Advanced Solid Tumors (MAGNETIC Study)
Phase 1, multi-center, open-label, dose-escalation study to:
- Evaluate the safety profile and MTD of RP-6306 with gemcitabine to establish the RP2D and schedule
- Characterize the PK and pharmacodynamics of RP-6306 with gemcitabine
- Assess preliminary anti-tumor activity associated with RP-6306 with gemcitabine